methyl 3,3-dimethyl-2-oxocyclopentanecarboxylate | 80969-68-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 3,3-dimethyl-2-oxocyclopentanecarboxylate
• 英文别名: methyl 3,3-dimethyl-2-oxocyclopentyl-1-carboxylate；2-oxo-3,3-dimethylcyclopentyl carboxylic acid methyl ester；Methyl 3,3-dimethyl-2-oxocyclopentane-1-carboxylate
• CAS: 80969-68-2
• 化学式: C₉H₁₄O₃
• 分子量: 170.208
• InChiKey: GQALPOWUSYCKFO-UHFFFAOYSA-N

物化性质

• 沸点：
  223.8±33.0 °C(Predicted)
• 密度：
  1.055±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3,3-dimethyl-2-oxocyclopentanecarboxylate 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氯化碳 、 乙醚 为溶剂， 反应 14.0h， 生成
  参考文献：
  名称：

  单环和双环膦酸酯作为酰基转移催化剂的比较。

  摘要：

  描述了手性膦11、15a，19a，24a和28a的合成和评估，它们是用于酸酐活化和醇动力学拆分的亲核催化剂。相对反应性在单环系列中遵循11a> 11b> 15a> 1的顺序，在双环系列中遵循24a> 19a> 28a的顺序，总速率优势约为。双环膦酸酯比单环类似物高2个数量级。双环膦酸酯对醇酰化反应性的增加归因于构象效应和基态不稳定的高度缔合机理。动力学分辨率数据证明了24a的前景良好的对映选择性。

  DOI：

  10.1021/jo030007+
• 作为产物：
  描述：

  2,2-二甲基己二酸二甲酯 生成 methyl 3,3-dimethyl-2-oxocyclopentanecarboxylate
  参考文献：
  名称：

  Does the dieckmann condensation occur in the gas phase?

  摘要：

  AbstractBurinsky and Cooks1 have reported that deprotonated dimethyl adipate eliminates methanol via a gas‐phase Dieckmann condensation. This is in contrast to the behaviour of simple methyl ester enolates which lose MeOH by a different mechanism, e.g. MeOCOC̄HCH2R → [MeO(OCCHCH2R)] → OCCHC̄HR + MeOH. Evidence is presented which supports the Dieckmann mechanism for adipates. For example, MeOCOC̄(Me)CH2CH2CD(Me)CO2Me should eliminate MeOD in a Dieckmann condensation, but MeOH by the alternative mechanism outlined above. Experimentally, MeOD is lost exclusively. Similarly, MeOCOC̄DCH2CH2C(Me)2CO2Me also loses MeOD, consistent with a Dieckmann process.

  DOI：

  10.1002/oms.1210231008

文献信息

• [EN] ORGANIC COMPOUND USED AS FRAGRANCE INGREDIENTS<br/>[FR] COMPOSÉ ORGANIQUE UTILISÉ COMME INGRÉDIENTS PARFUMÉS
  申请人：GIVAUDAN SA

  公开号：WO2017139920A1

  公开（公告）日：2017-08-24

  A compound of formula I wherein R1, R2, R3 and R4 can be independently selected from H or Me, n ＝ 0, 1, the dotted lines are indicating single bonds, or in case n ＝ 0 an isolated double bond at position 3', or in case n ＝ 1 an isolated double bond at position 3' or 4', and the wavy bond is indicating an unspecified configuration of the adjacent double bond. Said compounds, as well as precursors capable to generate said compounds, are useful as fragrance ingredients.

  式I的化合物，其中R1、R2、R3和R4可以独立地选择为H或Me，n = 0、1，虚线表示单键，或在n = 0的情况下，在3'位有一个孤立的双键，或在n = 1的情况下，在3'或4'位有一个孤立的双键，波浪键表示相邻双键的未指定构型。所述化合物以及能够生成所述化合物的前体可用作香料成分。
• THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF
  申请人：Terns, Inc.

  公开号：US20200190064A1

  公开（公告）日：2020-06-18

  The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

  本发明公开了一种由以下化学式（I）表示的化合物及其药用可接受的盐。该化合物在保持良好的THRβ激动活性的同时提高了对THRα的选择性，从而改善了最终药物的性能。
• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。
• 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04385062A1

  公开（公告）日：1983-05-24

  1-[(2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives of the formula ##STR1## wherein R, R.sup.1, and R.sup.2, each independently, represent hydrogen or a (C.sub.1 -C.sub.4)alkyl radical, n represents the integer 1, 2, 3, 4, or 5, and, in each of the n (CR'.sub.2) groups, R' represents hydrogen or (C.sub.1 -C.sub.4)alkyl, are described as well as the process for their manufacture, the intermediates for their synthesis and their use as antihypertensive agents.

  该文描述了公式## STR1##的1-[(2-巯基环烷基)羰基]-L-脯氨酸衍生物，其中R、R.sup.1和R.sup.2，各自独立地表示氢或(C.sub.1-C.sub.4)烷基基团，n表示整数1、2、3、4或5，在n个(CR'.sub.2)基团中，R'表示氢或(C.sub.1-C.sub.4)烷基。此外，还描述了它们的制造过程、合成的中间体以及它们作为降压剂的用途。
• Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis
  申请人：Honda Tadashi

  公开号：US10233146B2

  公开（公告）日：2019-03-19

  The present invention provides a compound having the structure: wherein X is C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, cyano, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl, alkenylheteroaryl, alkynylaryl, alkynylheteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, acyl, alkylhydroxy, alkylamino, alkenylamino, alkynylamino, amido, carboxyl, or carboxyl ester, or forms an unsubstituted or substituted cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, indane or tetralin with Y, Y is H or forms an unsubstituted or substituted cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, indane or tetralin with X, or forms an unsubstituted or substituted monocycle with Z; and Z is H or forms an unsubstituted or substituted monocycle with Y; wherein when X and Y are both H, then X is C2 alkenyl or C2 alkynyl, and when Y is H forms a substituted cyclohexyl, cycloheptyl with X, the cyclohexyl is other than a trisubstituted cyclohexyl bearing CH3, i-Pr and (CH2)2CO2CH3 groups or CH3, i-Pr and (CH2)3NH2, or a salt or ester thereof.

  本发明提供了一种具有以下结构的化合物： 其中 X是C1-C12烷基、C2-C12烯基、C2-C12炔基、氰基、芳基、杂芳基、烷芳基、烷基异芳基、烯芳基、烯基异芳基、炔芳基、炔基异芳基、烷氧基、烯氧基、炔氧基、芳氧基、杂芳氧基、酰基、烷基羟基、烷基氨基、烯基氨基、炔基氨基、氨基、羧基或羧基酯，或与 Y 形成未取代或取代的环丁基、环戊基、环己基、环庚基、茚或四萘、 Y 是 H，或与 X 形成未取代或取代的环丁基、环戊基、环己基、环庚基、茚满或四萘，或与 Z 形成未取代或取代的单环；和 Z 是 H，或与 Y 形成未取代或取代的单环； 其中，当 X 和 Y 均为 H 时，则 X 为 C2 烯基或 C2 炔基，而当 Y 为 H 时，则与 X 形成取代的环己基、环庚基，该环己基是三取代的环己基以外的环己基。 当 Y 为 H 与 X 形成取代的环己基、环庚基时，环己基不是含有 CH3、i-Pr 和 (CH2)2CO2CH3 基团或 CH3、i-Pr 和 (CH2)3NH2 的三取代环己基、 或其盐或酯。